A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT ID: NCT07220083

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-05

Study Completion Date

2029-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.

Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.

Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.

Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focal Segmental Glomerulosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 764198 treatment

Group Type EXPERIMENTAL

BI 764198

Intervention Type DRUG

BI 764198

Placebo treatment

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo matching BI 764198

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 764198

BI 764198

Intervention Type DRUG

Placebo

Placebo matching BI 764198

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female participants ≥12 years old on the day of signing informed consent/assent (Visit 1)
2. Weight of ≥40 kg at the screening visit (Visit 1)
3. Body mass index (BMI) of ≤40 kg/m² at the screening visit (Visit 1)
4. Participants with a diagnosis prior to the screening visit (Visit 1) of either:

* Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR
* Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test)
5. Urine protein-creatinine ratio (UPCR) ≥1500 mg/g based on the mean of the spot urine sample and first morning void urine sample (both assessed by central laboratory) at the screening visit (Visit 1)
6. Estimated glomerular filtration rate (eGFR)

* For adult participants (≥18 years): ≥25 mL/min/1.73 m² (chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on combined serum creatinine plus cystatin C) at the screening visit (Visit 1)

Exclusion Criteria

1. Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)
2. Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)
3. FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)
4. A history of organ transplantation or planned organ transplantation during the course of the trial
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Kidney Research

Alabaster, Alabama, United States

Site Status

Nephrology Consultants, LLC

Huntsville, Alabama, United States

Site Status

Amicis Research Center - Balboa

Granada Hills, California, United States

Site Status

Academic Medical Research Institute - Glendale

Los Angeles, California, United States

Site Status

North America Research Institute

San Dimas, California, United States

Site Status

Valiance Clinical Research-Tarzana-68237

Tarzana, California, United States

Site Status

National Institute of Clinical Research - Victorville

Victorville, California, United States

Site Status

Colorado Kidney Center

Denver, Colorado, United States

Site Status

Total Research Group, LLC

Miami, Florida, United States

Site Status

CTR Oakwater, LLC

Orlando, Florida, United States

Site Status

Panoramic Health

Riverview, Florida, United States

Site Status

Emory Children's Center

Atlanta, Georgia, United States

Site Status

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

Endeavor Health

Evanston, Illinois, United States

Site Status

Northwest Louisiana Nephrology

Shreveport, Louisiana, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

St. Clair Nephrology Research, LLC - Shelby Township

Utica, Michigan, United States

Site Status

Mayo Clinic, Rochester

Rochester, Minnesota, United States

Site Status

DaVita Clinical Research-Las Vegas-67781

Las Vegas, Nevada, United States

Site Status

New York Nephrology and Dialysis Access Surgery, PC

Clifton Park, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Brookview Hills Research Associates LLC

Winston-Salem, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Clinical Renal Associates

Exton, Pennsylvania, United States

Site Status

Southeast Renal Research Institute

Chattanooga, Tennessee, United States

Site Status

Texas Tech University Health Sciences Center-Amarillo-63885

Amarillo, Texas, United States

Site Status

Provecta Researh Network

Houston, Texas, United States

Site Status

Utah Kidney Research Institute

Salt Lake City, Utah, United States

Site Status

Virginia Nephrology

Arlington, Virginia, United States

Site Status

Terapia Renal Domiciliaria

Buenos Aires, , Argentina

Site Status

Hospital Italiano de Buenos Aires

CABA, , Argentina

Site Status

CEMIC

CABA, , Argentina

Site Status

Centro Medico Dra Laura Maffei

Ciudad Autonoma Buenos Aires, , Argentina

Site Status

Clinica Privada Velez Sarfield

Córdoba, , Argentina

Site Status

Hospital Universitario Austral

Pilar, , Argentina

Site Status

CardioAlem Investigaciones

San Isidro, , Argentina

Site Status

Nepean Hospital

Kingswood, New South Wales, Australia

Site Status

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Site Status

Griffith Health

Southport, Queensland, Australia

Site Status

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status

AZORG Ziekenhuis

Aalst, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Liège

Liège, , Belgium

Site Status

Synvia

Campinas, , Brazil

Site Status

Universidade Federal do Ceará

Fortaleza, , Brazil

Site Status

Hospital de Clínicas de Porto Alegre

Porto Alegre, , Brazil

Site Status

Universidade Federal Pernambuco

Recife, , Brazil

Site Status

Fundação Oswaldo Ramos (Hospital do Rim)

São Paulo, , Brazil

Site Status

Centro de Pesquisa Clínica de Nefrologia do ICHC

São Paulo, , Brazil

Site Status

The First Affiliated Hospital of Baotou Medical College

Baotou, , China

Site Status

Peking University First Hospital

Beijing, , China

Site Status

Beijing Tsinghua Changgung Hospital

Beijing, , China

Site Status

The Second Hospital of Jilin University

Changchun, , China

Site Status

The Second Xiangya Hospital Of Central South University

Changsha, , China

Site Status

West China Hospital of Sichuan University

Chengdu, , China

Site Status

People's Hospital of Sichuan Province

Chengdu, , China

Site Status

Guangdong Provincial People's Hospital

Guangzhou, , China

Site Status

Guizhou People's Hospital

Guiyang, , China

Site Status

The First Affiliated Hospital, Zhejiang University

Hangzhou, , China

Site Status

Lanzhou University Second Hospital

Lanzhou, , China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, , China

Site Status

Zhongda Hospital Southeast University

Nanjing, , China

Site Status

The First People's Hospital of Nanning

Nanning, , China

Site Status

The First Affiliated Hospital of Guangxi Medical University

Nanning, , China

Site Status

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

Shanghai General Hospital

Shanghai, , China

Site Status

Shanxi Provincial People's Hospital

Taiyuan, , China

Site Status

Renmin Hospital of Wuhan University

Wuhan, , China

Site Status

First Affiliated Hospital of Xi'an JiaoTong University

Xi'an, , China

Site Status

Zhongshan Hospital Affiliated to Xiamen University

Xiamen, , China

Site Status

Clinical Hospital Sveti Duh

Zagreb, , Croatia

Site Status

Poliklinika Bonifarm Zagreb

Zagreb, , Croatia

Site Status

Copenhagen University Hospital, Rigshospitalet

København Ø, , Denmark

Site Status

Zealand University Hospita; Roskilde

Roskilde, , Denmark

Site Status

HOP Amiens-Picardie Sud

Amiens, , France

Site Status

HOP Pellegrin

Bordeaux, , France

Site Status

HOP de la Cavale Blanche

Brest, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

HOP Edouard Herriot

Lyon, , France

Site Status

HOP Pasteur

Nice, , France

Site Status

HOP Nîmes

Nîmes, , France

Site Status

HOP Necker

Paris, , France

Site Status

HOP Nancy

Vandœuvre-lès-Nancy, , France

Site Status

Universitätsklinikum Köln (AöR)

Cologne, , Germany

Site Status

Universitätsklinikum Hamburg, Eppendorf

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Universität Leipzig

Leipzig, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, , Germany

Site Status

University General Hospital of Heraklion

Heraklion, , Greece

Site Status

Univ. Gen. Hosp. of Patras

Pátrai, , Greece

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Aartham Multi Super Speciality Hospital

Ahmedabad, , India

Site Status

Government Medical College

Kozhikode, , India

Site Status

Noble Hospital Pvt Ltd

Pune, , India

Site Status

Azienda Universitaria Ospedaliera Consorziale Policlinico Bari

Bari, , Italy

Site Status

Policlinico S. Orsola-Malpighi

Bologna, , Italy

Site Status

Asst Santi Paolo E Carlo

Milan, , Italy

Site Status

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Palermo, , Italy

Site Status

Fondazione Salvatore Maugeri

Pavia, , Italy

Site Status

ASST dei Sette Laghi

Varese, , Italy

Site Status

Kasugai Municipal Hospital

Aichi, Kasugai, , Japan

Site Status

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

Aichi, Nagoya, , Japan

Site Status

National Hospital Organization Chibahigashi National Hospital

Chiba, Chiba, , Japan

Site Status

Japanese Red Cross Fukuoka Hospital

Fukuoka, Fukuoka, , Japan

Site Status

Saiseikai Yokohamashi Nanbu Hospital

Kanagawa, Yokohama, , Japan

Site Status

Nara Prefecture General Medical Center

Nara, Nara, , Japan

Site Status

Dokkyo Medical University Saitama Medical Center

Saitama, Koshigaya, , Japan

Site Status

The Jikei University Hospital

Tokyo, Minato-ku, , Japan

Site Status

Hospital Kuala Lumpur

Kuala Lumpur, , Malaysia

Site Status

University of Malaya Medical Centre

Lembah Pantai, , Malaysia

Site Status

Sunway Medical Centre

Subang Jaya, , Malaysia

Site Status

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City, , Mexico

Site Status

Amsterdam UMC Locatie AMC

Amsterdam, , Netherlands

Site Status

Universitair Medisch Centrum Groningen

Groningen, , Netherlands

Site Status

Radboud Universitair Medisch Centrum

Nijmegen, , Netherlands

Site Status

Optimal Clinical Trials - Christchurch

Christchurch, , New Zealand

Site Status

Akershus Universitetssykehus HF

Lørenskog, , Norway

Site Status

Oslo Universitetssykehus HF, Ullevål sykehus

Oslo, , Norway

Site Status

Helse Stavanger, Stavanger Universitetssykehus

Stavanger, , Norway

Site Status

Universitetssykehuset Nord-Norge, Tromsø

Tromsø, , Norway

Site Status

Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi

Lodz, , Poland

Site Status

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Poznan, , Poland

Site Status

Pomorski Uniwersytet Medyczny w Szczecinie, Samodzielny Publiczny Szpital Kliniczny nr 2

Szczecin, , Poland

Site Status

Centralny Szpital Kliniczny MON WIM

Warsaw, , Poland

Site Status

ULS de Almada -Seixal, E. P. E. - Hospital Garcia de Orta

Almada, , Portugal

Site Status

ULS de Amadora/ Sintra, E.P.E. - Hospital Professor Doutor Fernando Fonseca

Amadora, , Portugal

Site Status

ULS Braga

Braga, , Portugal

Site Status

ULS de Coimbra, E.P.E.

Coimbra, , Portugal

Site Status

ULS de São José

Lisbon, , Portugal

Site Status

ULS de Santa Maria, E.P.E

Lisbon, , Portugal

Site Status

Unidade Local de Saúde Lisboa Occidental, E.P.E

Lisbon, , Portugal

Site Status

ULS de Loures-Odivelas, E.P.E

Loures, , Portugal

Site Status

ULS de Santo Antônio, E.P.E - Centro Hospitalar Universitário de Santo António

Porto, , Portugal

Site Status

Unidade Local de Saúde da Arrábida,E.P.E

Setúbal, , Portugal

Site Status

Fundeni Clinical Institute

Bucharest, , Romania

Site Status

Cluj Napoca Clinical County Hospital

Cluj-Napoca, , Romania

Site Status

National University Hospital

Singapore, , Singapore

Site Status

Singapore General Hospital

Singapore, , Singapore

Site Status

Tan Tock Seng Hospital

Singapore, , Singapore

Site Status

Univerzitna nemocnica L. Pasteura Kosice

Košice, , Slovakia

Site Status

Univ. Hospital Martin

Martin, , Slovakia

Site Status

Samsung Medical Center

Gangnam-gu, , South Korea

Site Status

Inje University Ilsan Paik Hospital

Goyang-si, , South Korea

Site Status

Complejo Hospitalario Torrecárdenas

Almería, , Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital Universitari Vall D Hebron

Barcelona, , Spain

Site Status

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status

Hospital Sant Joan de Déu

Barcelona, , Spain

Site Status

Hospital Universitario Virgen de las Nieves

Granada, , Spain

Site Status

Hospital Clínico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Danderyds Sjukhus

Danderyd, , Sweden

Site Status

Universitetssjukhuset, Linköping

Linköping, , Sweden

Site Status

Skånes universitetssjukhus

Lund, , Sweden

Site Status

Karolinska Universitetssjukhuset

Stockholm, , Sweden

Site Status

Uppsala University Hospital

Uppsala, , Sweden

Site Status

University Hospital Bern

Bern, , Switzerland

Site Status

Buddhist Tzu Chi General Hospital-Hualien-20741

Hualien City, , Taiwan

Site Status

Taipei Medical University-Shuang Ho Hospital

New Taipei City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Adana City Hospital

Adana, , Turkey (Türkiye)

Site Status

Ankara Etlik City Hospital

Ankara, , Turkey (Türkiye)

Site Status

Bursa Uludag University

Bursa, , Turkey (Türkiye)

Site Status

İstanbul Çapa University

Istanbul, , Turkey (Türkiye)

Site Status

Erciyes University

Melikgazi/Kayseri, , Turkey (Türkiye)

Site Status

Clatterbridge Hospital

Bebington, , United Kingdom

Site Status

NIHR Bradford and West Yorkshire CRDC

Bradford, , United Kingdom

Site Status

Leicester General Hospital

Leicester, , United Kingdom

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil China Croatia Denmark France Germany Greece Hong Kong India Italy Japan Malaysia Mexico Netherlands New Zealand Norway Poland Portugal Romania Singapore Slovakia South Korea Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Boehringer Ingelheim

Role: CONTACT

Phone: 1-800-243-0127

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Boehringer Ingelheim

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-522191-86

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1326-1647

Identifier Type: REGISTRY

Identifier Source: secondary_id

1434-0017

Identifier Type: -

Identifier Source: org_study_id